Sandoz opens high-volume biosimilar drug substance manufacturing center in Lendava, Slovenia

By Public Technologies
  • Sandoz Group AG opened a high-volume biosimilar drug-substance manufacturing center in Lendava, Slovenia, expanding in-house production capacity.
  • Facility strengthens supply flexibility across Sandoz’s European biosimilar network, supporting its Bio100 target of more than 100 biosimilars by 2040.
  • Site uses automation and process analytical technology from development through full-scale manufacturing, built to international safety, quality, environmental standards.
  • Expansion adds more than 300 staff, complementing continuous manufacturing in Toulouse and planned disposable fed-batch investment in Ljubljana.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2406294_en) on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.